NCT06522386 2026-04-16
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT05529069 2026-04-15
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06553872 2026-03-31
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06263491 2026-03-20
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05990465 2026-02-23
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT07285590 2025-12-16
IMCL-2023
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT06252675 2025-10-22
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
Phase 2 Recruiting
NCT07207785 2025-10-06
FIL_PUMA
Fondazione Italiana Linfomi - ETS
Phase 2 Not yet recruiting
NCT05833763 2024-01-08
GOlDiLOX
Australasian Leukaemia and Lymphoma Group
Phase 2 Recruiting